Astellas’ Vaprisol Receives Second Indication
Vasopressin antagonist clears FDA for treatment of hospitalized patients with hypervolemic hyponatremia.
Vasopressin antagonist clears FDA for treatment of hospitalized patients with hypervolemic hyponatremia.